Cell therapy for moderate to severe ARDS caused by infection
Part of Lungs & breathing clinical trials.
This study tests an experimental cell therapy (GKL-006RTU) for people with moderate to severe ARDS caused by an infection. If you qualify, you may receive this treatment alongside standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with moderate to severe ARDS (a serious lung condition) caused by an infection—not from trauma or other causes.
- You have been receiving treatment (antibiotics and lung support) for at least 24 hours.
- You do not have certain infections (like active hepatitis B/C, HIV, or syphilis) and are not on strong immune-suppressing drugs.
- You do not have severe heart, liver, kidney, or blood problems, and are not expected to need a heart-lung machine (ECMO).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This early-stage trial tests whether an inhaled medication called recombinant human keratinocyte growth factor-2 (rh-KGF-2) can help patients with acute respiratory distress syndrome (ARDS)—a serious condition where the lungs cannot deliver enough oxygen to the blood. The drug is designed to help repair lung tissue damage.
This study looks at how the immune system responds in people with ARDS (a severe lung injury) and tests a new treatment called PIP-2 in the lab to see if it might help. It aims to better understand lung injury and find new ways to treat it.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This trial tests whether an injection of stem cells from umbilical cords can help people with severe ARDS (a type of lung failure) recover faster. It is for those who have not improved after standard treatment and whose ARDS is caused by an infection (not COVID-19).
This trial tests whether human umbilical cord mesenchymal stem cells given through an IV can help people with severe ARDS. It aims to see if the treatment is safe and if it can improve breathing and recovery.
Hear when a new ARDS (Acute Respiratory Distress Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.